CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway

BACKGROUND: In colorectal cancer, CDX2 expression is lost in approximately 20% of cases and associated with poor outcome. Here, we aim to validate the clinical impact of CDX2 and investigate the role of promoter methylation and histone deacetylation in CDX2 repression and restoration. METHODS: CDX2...

Descripción completa

Detalles Bibliográficos
Autores principales: Graule, Janina, Uth, Kristin, Fischer, Elia, Centeno, Irene, Galván, José A., Eichmann, Micha, Rau, Tilman T., Langer, Rupert, Dawson, Heather, Nitsche, Ulrich, Traeger, Peter, Berger, Martin D., Schnüriger, Beat, Hädrich, Marion, Studer, Peter, Inderbitzin, Daniel, Lugli, Alessandro, Tschan, Mario P., Zlobec, Inti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158822/
https://www.ncbi.nlm.nih.gov/pubmed/30257705
http://dx.doi.org/10.1186/s13148-018-0548-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158822/
https://www.ncbi.nlm.nih.gov/pubmed/30257705
http://dx.doi.org/10.1186/s13148-018-0548-2

Ejemplares similares